Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Method for preventing or treating skin tumor

a skin tumor and adrenergic receptor technology, applied in the field of skin tumor prevention or treatment, can solve the problems of significant regression in skin tumor growth in subjects exposed to uv radiation, significant delay in skin tumor formation, etc., and achieve the effect of safe and effective amount of 2 adrenergic receptor agonis

Inactive Publication Date: 2015-04-09
GALDERMA RES & DEV SNC
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The technical effects of this patent are not explicitly mentioned, but it describes a new invention and its preferred embodiments. The patent aims to provide a detailed description of the invention and the benefits it may offer in a simple language for easy understanding by R&D personnel.

Problems solved by technology

It is now surprisingly discovered that treatment with an α2 adrenergic receptor agonist has resulted in a significant delay of skin tumor formation and a significant regression in skin tumor growth in subjects exposed to UV radiation.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for preventing or treating skin tumor
  • Method for preventing or treating skin tumor
  • Method for preventing or treating skin tumor

Examples

Experimental program
Comparison scheme
Effect test

example 1

Aqueous Topical Formulations

[0099]This example illustrates aqueous topical formulations that can be used in the present invention.

[0100]A first aqueous solution topical formulation comprises: brimonidine tartrate (0.01% to 5% w / w); Puriteg (0.005% w / w) (stabilized chlorine dioxide) as a preservative; and the inactive ingredients: boric acid; calcium chloride; magnesium chloride; potassium chloride; purified water; sodium borate; sodium carboxymethylcellulose; sodium chloride; with hydrochloric acid and / or sodium hydroxide to adjust the pH to 5.6 to 6.6. The osmolality is in the range of 250-350 mOsmol / kg.

[0101]A second aqueous solution topical formulation comprises brimonidine tartrate (0.2% to 2% w / w); benzalkonium chloride (0.005% w / w.) as a preservative; and the inactive ingredients: boric acid; calcium chloride; magnesium chloride; potassium chloride; purified water; sodium borate; sodium carboxymethylcellulose; sodium chloride; with hydrochloric acid and / or sodium hydroxide to ...

example 2

Cream or Ointment Topical Formulations

[0102]This example illustrates cream or ointment topical formulations that can be used in the present invention.

[0103]A first cream topical formulation (hydrophilic ointment) is described in Table 2 below.

TABLE 2IngredientWeight PercentBrimonidine tartrate0.01% to 5%Stearic acid  7%Stearyl alcohol5% Cetyl alcohol2% Glycerin  10%Sodium lauryl sulfate  1%Propylparaben0.05%Methylparaben0.25%Disodium edetate0.055% Distilled waterQSTOTAL 100%

[0104]To make the formulation, the stearyl alcohol and the white petrolatum are melted on a steam bath, and warmed to about 75 degrees C. The other ingredients, previously dissolved in the water and warmed to 75 degrees C., are then added, and the mixture is stirred until it congeals. The mixture is then allowed to cool with stirring, and brimonidine tartrate is then added as a concentrated solution.

[0105]An ointment topical formulation (hydrophilic ointment) is described in Table 3 below.

TABLE 3IngredientsWeight...

example 3

Gel Topical Formulations

[0107]This example illustrates gel topical formulations that can be used in the present invention.

[0108]A first gel formulation is described in Table 4 below.

TABLE 4IngredientsWeight %Brimonidine tartrate0.01-5%  Methylparaben NF0.15%Propylparaben NF0.03%Hydroxyethylcellulose NF1.25%Disodium Edetate USP0.05%Purified Water, USPQSTOTAL 100%

[0109]A second gel formulation is described in Table 5 below.

TABLE 5IngredientsWeight %Brimonidine tartrate 0.5%Methylparaben0.20%Propylparaben0.05%Carbomer 934P NF 1.0%Sodium HydroxideQS pH 7Purified Water, USPQSTOTAL 100%

[0110]The ingredients are mixed together and aqueous sodium hydroxide is slowly added to the mixture until a pH of about 7 is reached and the gel is formed.

[0111]A third gel formulation is described in Table 6 below.

TABLE 6IngredientWeight PercentBrimonidine tartrate0.1-2%  Carbomer 934P1.25% Methylparaben0.3%Phenoxyethanol0.4%Glycerin5.5%10% Titanium dioxide0.625% Propylene glycol5.5%10% NaOH Solution6.5%D...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Methods, compositions and products for preventing skin tumor formation or inhibiting the development of an existing skin tumor in a subject are described. The methods involve administering to the subject a composition containing an α2 adrenergic receptor agonist, such as brimonidine.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a Continuation of U.S. application Ser. No. 13 / 821,145, which is a Section 371 of International Application No. PCT / EP2011 / 060939, filed Jun. 29, 2011, which was published in the English language on Jan. 5, 2012, under International Publication No. WO 2012 / 001065 A1, and the disclosure of which is incorporated herein by reference.BACKGROUND OF THE INVENTION[0002]UV radiation has been shown to be a cause for a wide spectrum of skin damage, from premature aging to skin cancer, the most prevalent of all cancers in the United States. Skin cancer is a malignant neoplasm of the epidermis / dermis, i.e., it has uncontrolled growth, invades nearby tissue, and if left untreated, may spread throughout the body, metastasizing and eventually killing the host. Basal cell and squamous cell carcinomas represent the majority of skin cancer cases. The leading cause of death due to skin cancer is from malignant melanoma. It is estimated t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K8/49A61Q17/04
CPCA61Q17/04A61K8/4946A61K9/0014A61K9/12A61K31/137A61K31/4174A61K31/502A61K47/06A61K47/10A61K47/32A61K47/38A61K2800/78A61P17/00A61P35/00A61K31/498
Inventor BOUVIER, GUYLEONI, MATTHEW JAMESGRAEBER, MICHAEL
Owner GALDERMA RES & DEV SNC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com